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changes between 2000–2004 in inpatient care, home care,
CT/MRI examinations. CONCLUSIONS: The budgets of drug
and medical devices reimbursement are highly concentrated
while the distribution of renal dialysis expenditures was the most
linear. Gini coefﬁcient of inpatient care, home care and CT/MRI
examinations showed signiﬁcant time trend.
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OBJECTIVES: Prescription drug prices between Canadian and
US on-line pharmacies were studied over a 6-month period.
METHODS: Prices for 28 popular brand name medications were
collected from eight Canadian and ﬁve US on-line pharmacies
weekly for six months. Prices were compared between Canadian
and US on-line pharmacies, and price changes were monitored
each week. RESULTS: During the study period, purchasing from
Canadian on-line pharmacies would save consumers >$1.00 per
unit for 12 drugs (42.9%). Savings were demonstrated in two
drugs if purchased from US on-line pharmacies: sildenaﬁl 25mg
($2.06/unit) and amlodipine 10mg ($0.02/unit). Average price
increases from the ﬁrst to the last week of the 6-month period
were greater from Canadian on-line pharmacies ($0.10/unit)
compared to the US ($0.07/unit). From Canadian on-line phar-
macies, prices from all the medications increased during the
study period except one, which stayed the same. The two drugs
with the greatest price increases were alendronate 70mg
($1.04/unit) and sildenaﬁl 25mg ($0.45/unit). From US on-line
pharmacies, nine drug prices decreased during the study period,
four remained the same, and 15 increased. The greatest price
increases were for alendronate 70mg ($0.62/unit) and olanzap-
ine 10mg ($0.41/unit). Consumer savings from purchasing
Canadian on-line drugs decreased from the ﬁrst to the last week
of the 6-month period for 17 medications (60.7%), with the
greatest decrease in savings being for 100 units of gabapentin
300mg (19.4% decrease) and sertraline 100mg (15.1%
decrease). CONCLUSIONS: When 100% of prescription drug
payments are out-of-pocket, consumers usually save money
when buying from Canadian on-line pharmacies. Although
prices were lower using these pharmacies, price increases over
the study period were greater. In order to get the best price for
medications purchased on-line, one would need to compare
prices from multiple pharmacies in Canada and the US for each
prescription drug over a period of time.
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OBJECTIVES: Specialty pharmaceuticals account for a signiﬁ-
cant and growing proportion of health plans’ pharmacy budget.
This research examined how insurance type, deﬁned as tradi-
tional (TRAD), managed care (MC) or preferred provider orga-
nization (PPO), affects a plan’s annual per enrollee and per
patient expenditures on specialty pharmaceuticals. METHODS:
Three years (2002–2004) of outpatient specialty pharmaceuticals
claims data, extracted based on a predeﬁned list of HCPCS, CPT
and NDC codes, from 15 BlueCross and BlueShield plans were
used to construct ﬁxed effect panel data models. Because of
potential adverse selection and dual insurance coverage in the
65+ age group, this study focused on the under 65 age group.
Covariates included in the models were plan, year, insurance type
and drug categories. Model parameters were estimated using
generalized estimating equations (GEE). RESULTS: Plan and
drug categories were signiﬁcant covariates in models estimating
per enrollee as well as per patient expenditures. Adjusted per
enrollee expenditure increased 39.6% from 2002 to 2003 and
27.8% from 2003 to 2004. Per enrollee expenditure was 20.3%
(p = 0.0215, 95% CI: 3.3–34.3%) lower in MC and 39.5% (p
< 0.001, 95% CI: 27.7–49.3%) lower in PPO than TRAD plans.
PPO plans had 24.1% (p = 0.015, 95% CI: 10.0–35.9%) lower
per enrollee expenditure than MC plans. Adjusted per patient
expenditure increased 15.3% from 2002 to 2003 and 10.8%
from 2003 to 2004. Insurance type was not signiﬁcantly 
associated with per patient expenditure. CONCLUSIONS: A
plan’s per enrollee expenditure on outpatient specialty pharma-
ceuticals differed across insurance type. TRAD had the highest
per enrollee expenditure, followed by MC and then PPO 
plans. However, insurance type did not signiﬁcantly affect 
a health plan’s per patient expenditure on outpatient 
specialty pharmaceuticals.
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OBJECTIVES: To estimate the return on investment (ROI) asso-
ciated with database integration technology enabling automated
bidirectional sharing of patient data between a hospice and
hospice pharmacy provider. METHODS: ROI was calculated as
total direct savings (TDS) and payback period in years (PPY).
Formula inputs were costs of implementing a bidirectional 
interface between the pharmacy and hospice, and costs of 
telephone/fax transmission of demographic and medication data.
The net present value (NPV) adjusted for inﬂation was used to
forecast future cash inﬂows across three years. RESULTS: Esti-
mated annual savings for unidirectional interface were $7500
and bidirectional savings were $22,500 for a hospice admitting
300 patients/month, assuming $50,000 nurse salary. Hospice
nurses were assumed to use wireless phones for transmission of
patient admission data. Replacement of voice with interface
resulted in estimated savings of $1800 annually. Telephone
savings for medication proﬁle data transmission yielded $1620
annually. After summing the immediate gains of recovered time
inefﬁciencies and reduced telephone usage, implementation of a
pharmacy/hospice interface resulted in TDS of $33,420 annually.
The discounted or investment yield rate utilized was 10%. There-
fore, while projected total net savings generated by a phar-
macy/hospice interface across 3 years equaled $100,260, the
total NPV, reﬂecting the time value of money, was $84,596. The
annual ROI represented by the NPV of the pharmacy/hospice
interface was 1127.94%. The PPY (breakeven analysis) in which
the ﬁnancial beneﬁts exceed the initial investment would be
reached in 0.27 years. CONCLUSIONS: “Low-tech” bias and
lack of capital for investment in technology have contributed to
a lag in adoption of technological innovations in hospice. Pro-
jected ROI for automated data sharing via interface suggested
considerable decrease in administrative costs. Hospice adminis-
trators could apply the formulas used in this study with their
unique data to forecast ROI in their settings.
